Pathophysiology: Wegener's granulomatosis is a systemic autoimmune disease characterized by granulomatous vasculitis of the upper and lower respiratory tracts, glomerulonephritis and small vessel vasculitis. 90% of patients have pulmonary involvement. As the affected vessels are occluded, stroke developed with subsequent radiographic manifestations of ill-defined multiple bilateral opacities and delimit as myocardial is organized.
Medications such as prednisone help suppress the immune system and treat the early signs and symptoms of Wegener's granulomatosis.
Most people require another immunosuppressive drug, such as cyclophosphamide, azathioprine or methotrexate, to counteract the body's immune reaction.
Department of Endocrinology, Hospital Gene Pituitary participation has been described in 24 patients in the literature to date. A case of pituitary involvement in WG, and to present a literature review on this association. ral de Agudos Dr. Profesor J. M. Ramos Mejía conducted a research on Wegener's granulomatosis. They present a female patient with WG who evolved with central diabetes insipidus (CDI), panhypopituitarism, and mild hyperprolactinemia. MRI showed an infiltrative pattern.
Statistics: The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or renal failure. Even non-renal GPA carries a mortality rate of up to 40%.